- Home
- FXNC vs TLSI Comparison
FXNC vs TLSI Comparison
Compare FXNC & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FXNC
- TLSI
- Stock Information
- Founded
- FXNC 1907
- TLSI 2010
- Country
- FXNC United States
- TLSI United States
- Employees
- FXNC N/A
- TLSI N/A
- Industry
- FXNC Major Banks
- TLSI Medical Specialities
- Sector
- FXNC Finance
- TLSI Health Care
- Exchange
- FXNC Nasdaq
- TLSI Nasdaq
- Market Cap
- FXNC 203.9M
- TLSI 244.3M
- IPO Year
- FXNC N/A
- TLSI N/A
- Fundamental
- Price
- FXNC $23.08
- TLSI $4.40
- Analyst Decision
- FXNC
- TLSI Strong Buy
- Analyst Count
- FXNC 0
- TLSI 3
- Target Price
- FXNC N/A
- TLSI $10.67
- AVG Volume (30 Days)
- FXNC 16.2K
- TLSI 104.5K
- Earning Date
- FXNC 10-30-2025
- TLSI 11-13-2025
- Dividend Yield
- FXNC 2.68%
- TLSI N/A
- EPS Growth
- FXNC 10.96
- TLSI N/A
- EPS
- FXNC 1.24
- TLSI N/A
- Revenue
- FXNC $81,109,000.00
- TLSI $35,990,000.00
- Revenue This Year
- FXNC $57.18
- TLSI $57.25
- Revenue Next Year
- FXNC $5.15
- TLSI $54.05
- P/E Ratio
- FXNC $18.61
- TLSI N/A
- Revenue Growth
- FXNC 66.52
- TLSI 45.50
- 52 Week Low
- FXNC $18.26
- TLSI $3.42
- 52 Week High
- FXNC $26.97
- TLSI $5.88
- Technical
- Relative Strength Index (RSI)
- FXNC 60.09
- TLSI 38.33
- Support Level
- FXNC $22.10
- TLSI $4.50
- Resistance Level
- FXNC $23.20
- TLSI $4.80
- Average True Range (ATR)
- FXNC 0.45
- TLSI 0.22
- MACD
- FXNC 0.09
- TLSI -0.06
- Stochastic Oscillator
- FXNC 93.82
- TLSI 17.58
About FXNC First National Corporation
First National Corp is a bank holding company of First Bank, which is a commercial bank. Its core offering includes loans, deposits, wealth management, and other products and services. The Company operates through two reportable operating segments: Community Banking and wealth management. The Community Banking segment involves making loans and generating deposits from individuals, businesses, and charitable organizations. Wealth Management Services offers corporate trustee services, trust and estate administration, IRA administration and custody services. Key revenue is generated from Community Banking.
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product linesPressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.